10 Hot Biotech Stocks Under $5 to Buy
On June 4, 2026, CNBC reported that global biopharma M&A is on track for its strongest year since the pre-pandemic peak seven years ago.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Suvretta Capital Management Aaron Cowen | 22,933,910 | $51,371,958 | +190% | 0.94% |
| 2. | Commodore Capital Egen Atkinson And Michael Kramarz | 7,300,000 | $16,352,000 | 0.97% | |
| 3. | Spruce Street Capital Alex Rosen And Simon Basseyn | 5,352,198 | $11,988,924 | 2.35% | |
| 4. | 683 Capital Partners Ari Zweiman | 5,065,000 | $11,345,600 | +53% | 0.56% |
| 5. | Farallon Capital Thomas Steyer | 3,325,000 | $7,448,000 | 0.03% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,500,000 | $32,480,000 | 0.78% | |
| 2. | 8,163,341 | $18,285,884 | 0% | |
| 3. | 2,572,799 | $5,763,070 | 0% | |
| 4. | 1,036,118 | $2,320,904 | 0% | |
| 5. | 915,614 | $2,050,975 | 0% |